Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone

Diabetic Medicine : a Journal of the British Diabetic Association
Y IwamotoT Kaneko

Abstract

The clinical efficacy of troglitazone, a new oral hypoglycaemic agent was investigated in Type 2 diabetes in combination with sulphonylureas. Two hundred and ninety-one patients with Type 2 diabetes (age 21-81 years) whose previous glycaemic control by sulphonylureas was judged stable but unsatisfactory (fasting plasma glucose (FPG) > 8.3 mmol I-1) were randomly allocated into the troglitazone treatment group (troglitazone group, n = 145) or the placebo treatment group (placebo group, n = 146). They were treated by test drugs for 12 weeks in combination with the same dose of sulphonylureas before the trial. One hundred and twenty-two patients who received troglitazone and 126 patients who received placebo were evaluated for efficacy. The baseline characteristics did not differ significantly between the two groups. In the troglitazone group, FPG and HbA(1c) decreased significantly after the treatment (before vs after, FPG: 10.8 +/- 2.0 mmol I(-1) vs 9.2 +/- 2.5 mmol I(-1), p< 0.001; HbA(1c): 9.2 +/- 1.4% vs 8.5 +/- 1.5%, p< 0.001). FPG and HbA(1c) did not change after the treatment in the placebo group (before vs after, FPG: 10.5 +/- 1.7 mmol I(-1) vs 10.7 +/- 2.2 mmol I(-1); HbA(1c): 9.0 +/- 1.5% vs 9.2 +/- 1.6 %). Serum total ...Continue Reading

Citations

Jul 21, 2000·The Western Journal of Medicine·D Krische
Mar 27, 1998·The New England Journal of Medicine·S E InzucchiG I Shulman
Nov 4, 2000·Expert Opinion on Investigational Drugs·E Murphy, J J Nolan
Jun 1, 1997·Expert Opinion on Investigational Drugs·A J Mackay, J R Petrie
Mar 3, 1999·Clinical and Experimental Hypertension : CHE·R J Jha
Mar 28, 2002·The Journal of Toxicological Sciences·Charles RothwellFelix A de la Iglesia
May 5, 1999·Diabetic Medicine : a Journal of the British Diabetic Association·C Day
Nov 20, 2002·Expert Opinion on Pharmacotherapy·Charles J GlueckPing Wang
Aug 13, 1998·Transplantation·S J BurgessD C Brennan
Oct 16, 2002·Current Cardiology Reports·Annaswamy Raji, Jorge Plutzky
Aug 18, 2017·Critical Reviews in Toxicology·Melissa A DavidsonDaniel Krewski
Aug 17, 2000·Current Opinion in Lipidology·S SunayamaH Yamaguchi
Jan 2, 2001·Endocrine Reviews·S MatthaeiH U Häring
Mar 10, 2001·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·D Kumar
Mar 14, 2003·The Diabetes Educator·UNKNOWN American Association of Diabetes Educators
Jul 15, 2004·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·S Mudaliar, R R Henry
Jun 23, 2001·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·K S Hershon, P M Hershon
Aug 6, 2000·The Annals of Pharmacotherapy·M S Rendell, W R Kirchain

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.